The new headquarters in aspern Seestadt, Vienna, will go into operation in Q1/2022. The new site will nearly double Biomay's headcount, from 50 at present to 90 going forward.
For more than a decade, Biomay has been successful as a biopharmaceutical contract development and manufacturing organization (CDMO) with an international reach. In particular, Biomay is recognized as a manufacturer of plasmid DNA (pDNA). Biomay´s clients include startups, midsize biotech companies and multinational enterprises, predominantly from Europe and the US.
Biomay has been manufacturing recombinant proteins since the 1990s and already holds the manufacturing license for another innovative and sought-after product class, messenger RNA (mRNA). Beside the manufacturing of active ingredients and drug products according to GMP standards, the company offers process and assay development as well as manufacturing of microbial cell banks.
Read more about the Austrian life sciences sector on the upswing.